Goldman Sachs
DAWN

Goldman Sachs’s Day One Biopharmaceuticals DAWN Stock Holding History

Goldman Sachs’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21M Sell
979,238
-526,996
-35% -$7.43M ﹤0.01% 2390
2025
Q4 		$14M Buy
1,506,234
+134,797
+10% +$1.13M ﹤0.01% 2732
2025
Q3 		$9.67M Sell
1,371,437
-319,849
-19% -$2.2M ﹤0.01% 3006
2025
Q2 		$11M Buy
1,691,286
+121,368
+8% +$835K ﹤0.01% 2673
2025
Q1 		$12.4M Buy
1,569,918
+1,097,679
+232% +$11.8M ﹤0.01% 2481
2024
Q4 		$5.98M Sell
472,239
-1,302,068
-73% -$18.1M ﹤0.01% 3275
2024
Q3 		$24.7M Sell
1,774,307
-128,801
-7% -$1.84M ﹤0.01% 1868
2024
Q2 		$26.2M Sell
1,903,108
-234,383
-11% -$3.43M ﹤0.01% 1665
2024
Q1 		$35.3M Buy
2,137,491
+18,642
+0.9% +$279K 0.01% 1400
2023
Q4 		$30.9M Buy
2,118,849
+472,654
+29% +$5.73M 0.01% 1528
2023
Q3 		$20.2M Sell
1,646,195
-746,328
-31% -$9.74M ﹤0.01% 1790
2023
Q2 		$28.6M Buy
2,392,523
+109,187
+5% +$1.43M 0.01% 1552
2023
Q1 		$30.5M Buy
2,283,336
+515,234
+29% +$10.1M 0.01% 1439
2022
Q4 		$38M Buy
1,768,102
+42,960
+2% +$881K 0.01% 1397
2022
Q3 		$34.6M Sell
1,725,142
-169,395
-9% -$3.6M 0.01% 1392
2022
Q2 		$33.9M Buy
1,894,537
+1,863,325
+5,970% +$19.2M 0.01% 1432
2022
Q1 		$310K Buy
31,212
+6,666
+27% +$88.1K ﹤0.01% 5642
2021
Q4 		$414K Buy
+24,546
New +$504K ﹤0.01% 5489
2021
Q3 		– Sell
-11,594
Closed -$264K – 6275
2021
Q2 		$264K Buy
+11,594
New +$242K ﹤0.01% 5597

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Goldman Sachs's DAWN Position: Q1 2026 in Review

Goldman Sachs reduced its Day One Biopharmaceuticals (DAWN) stake by 35% in Q1 2026, selling an estimated $7.43M and leaving 979,238 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2390.

Goldman Sachs first reported a position in DAWN in Q2 2021 and has held it in 19 quarters since. The position peaked at $38M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Goldman Sachs held 979,238 shares of Day One Biopharmaceuticals worth $21M as of Q1 2026.
  • Goldman Sachs sold 526,996 Day One Biopharmaceuticals shares in Q1 2026, an estimated $7.43M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2390 holding.
  • Goldman Sachs first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Day One Biopharmaceuticals position peaked at $38M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.